Phototherapy, photodynamic therapy and photophoresis in the treatment of connective-tissue diseases: a review
Corresponding Author
E.A. Gordon Spratt
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 240 East 38th Street, Floor 11, New York, 10016 NY, U.S.A
Correspondence
Elizabeth A. Gordon Spratt.
E-mail: [email protected]
Search for more papers by this authorL.V. Gorcey
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 240 East 38th Street, Floor 11, New York, 10016 NY, U.S.A
Search for more papers by this authorN.A. Soter
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 240 East 38th Street, Floor 11, New York, 10016 NY, U.S.A
Search for more papers by this authorJ.A. Brauer
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 240 East 38th Street, Floor 11, New York, 10016 NY, U.S.A
Laser & Skin Surgery Center of New York, New York, NY, U.S.A
Search for more papers by this authorCorresponding Author
E.A. Gordon Spratt
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 240 East 38th Street, Floor 11, New York, 10016 NY, U.S.A
Correspondence
Elizabeth A. Gordon Spratt.
E-mail: [email protected]
Search for more papers by this authorL.V. Gorcey
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 240 East 38th Street, Floor 11, New York, 10016 NY, U.S.A
Search for more papers by this authorN.A. Soter
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 240 East 38th Street, Floor 11, New York, 10016 NY, U.S.A
Search for more papers by this authorJ.A. Brauer
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 240 East 38th Street, Floor 11, New York, 10016 NY, U.S.A
Laser & Skin Surgery Center of New York, New York, NY, U.S.A
Search for more papers by this authorSummary
Connective-tissue disorders, which include lupus erythematosus, morphoea/scleroderma and dermatomyositis, are characterized by cutaneous manifestations that are sometimes resistant to conventional therapy. Light treatments, which include phototherapy, photodynamic therapy (PDT) and photopheresis, are routinely utilized in the treatment of dermatological conditions and may provide unique mechanisms of action in the treatment of these connective-tissue disorders. The objective of this study is to conduct a review of the literature that describes the use of phototherapy, PDT and photopheresis in the treatment of lupus erythematosus, morphoea/scleroderma and dermatomyositis. A MEDLINE search was conducted to find articles that discuss treatment of connective-tissue diseases with light therapies and more than 30 publications that discuss light therapy for these diseases were identified. These range in design from case reports to randomized, prospective trials. Study outcomes and details were summarized and presented within each connective-tissue disease by light therapy modality, which includes phototherapy, PDT and photopheresis. Although there is a known association between photosensitivity and connective-tissue diseases, light therapies, when used appropriately, may be legitimate therapeutic options for recalcitrant cutaneous manifestations in lupus erythematosus, morphoea/scleroderma and dermatomyositis.
References
- 1Alster TS, Lupton JR. Nonablative cutaneous remodeling using radiofrequency devices. Clin Dermatol 2007; 25: 487–91.
- 2Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies. Clin Dermatol 2013; 31: 438–54.
- 3Bulat V, Situm M, Dediol I et al. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol 2011; 35(Suppl. 2): 147–51.
- 4Chen J, Keltner L, Christophersen J et al. New technology for deep light distribution in tissue for phototherapy. Cancer J 2002; 8: 154–63.
- 5Holbrook MR, Powell RJ. Is there a future for extracorporeal photochemotherapy in the treatment of the rheumatological diseases? Ann Rheum Dis 1997; 56: 339–40.
- 6Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999; 318: 593–6.
- 7McGrath H Jr. Ultraviolet Al (340–400 nm) irradiation and systemic lupus erythematosus. J Investig Dermatol Symp Proc 1999; 4: 79–84.
- 8Cohen MR, Isenberg DA. Ultraviolet irradiation in systemic lupus erythematosus: friend or foe? Br J Rheumatol 1996; 35: 1002–7.
- 9Pavel S. Light therapy (with UVA-1) for SLE patients: is it a good or bad idea? Rheumatology (Oxford) 2006; 45: 653–5.
- 10Boeckler P, Liu V, Lipsker D. Extracorporeal photopheresis in recalcitrant lupus erythematosus. Clin Exp Dermatol 2009; 34: e295–6.
- 11Knobler RM, Graninger W, Lindmaier A et al. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthritis Rheum 1992; 35: 319–24.
- 12Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 2011; 65: 925–41.
- 13Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011; 64: 231–42.
- 14Kreuter A, Hyun J, Stüucker M et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54: 440–7.
- 15Vasquez R, Jabbar A, Khan F et al. Recurrence of morphea after successful ultraviolet al phototherapy: a cohort study. J Am Acad Dermatol 2014; 70: 481–8.
- 16Batchelor R, Lamb S, Goulden V et al. Photodynamic therapy for the treatment of morphoea. Clin Exp Dermatol 2008; 33: 661–3.
- 17Karrer S, Abels C, Landthaler M, Szeimies RM. Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol 2000; 80: 26–7.
- 18Knobler RM, French LE, Kim Y et al. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 2006; 54: 793–9.
- 19Enomoto DN, Mekkes JR, Bossuyt PM et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999; 41: 915–22.
- 20De Wilde A, DiSpaltro FX, Geller A et al. Extracorporeal photochemotherapy as adjunctive treatment in juvenile dermatomyositis: a case report. Arch Dermatol 1992; 128: 1656–7.
- 21Kim NN, Lio PA, Morgan GA et al. Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol 2011; 147: 831–5.
- 22Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol 1994; 131: 205–8.
- 23Sinoway PA, Davidson CL, Callen JP. Dermatomyositis occurring during psoralen A (PUVA) therapy. J Rheumatol 1994; 21: 353–6.
- 24McGrath H Jr. Ultraviolet-A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 129–35.
- 25McGrath H, Martinez-Osuna P, Lee FA. Ultraviolet-A1 (340–400 nm) irradiation therapy in systemic lupus erythematosus. Lupus 1996; 5: 269–74.
- 26Polderman MC, Le Cessie S, Huizinga TW, Pavel S. Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 1402–4.
- 27Polderman MC, Huizinga TW, Le Cessie S, Pavel S. UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial. Ann Rheum Dis 2001; 60: 112–15.
- 28Molina JF, McGrath H Jr. Longterm ultraviolet-A1 irradiation therapy in systemic lupus erythematosus. J Rheumatol 1997; 24: 1072–4.
- 29McGrath H Jr. Elimination of anticardiolipin antibodies and cessation of cognitive decline in a UV-A1-irradiated systemic lupus erythematosus patient. Lupus 2005; 14: 859–61.
- 30Romero-Maté A, Castaño-Suárez E, García-Donoso C et al. Unsuccessful treatment of recalcitrant cutaneous discoid lupus erythematosus with photodynamic therapy. Photodermatol Photoimmunol Photomed 2010; 26: 156–8.
- 31Fernández-Guarino M, Pérez-García B, Harto A, Jaén P. Discoid lupus erythematosus: good response to treatment with photodynamic therapy. J Eur Acad Dermatol Venereol 2008; 22: 1142–3.
- 32Fai D, Romano I, Cassano N, Vena GA. Cutaneous lupus erythematosus of the scalp treated with methyl-aminolevulinate photodynamic therapy: a case report. G Ital Dermatol Venereol 2012; 147: 213–15.
- 33Motta S, Monti M. Photodynamic therapy – a promising treatment option for autoimmune skin ulcers: a case report. Photochem Photobiol Sci 2007; 6: 1150–1.
- 34Wollina U, Looks A. Extracorporeal photochemotherapy in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 1999; 13: 127–30.
- 35Kerscher M, Meurer M, Sander C et al. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol 1996; 132: 1280–2.
- 36Buense R, Duarte IA, Bouer M. Localized scleroderma: assessment of the therapeutic response to phototherapy. An Bras Dermatol 2012; 87: 63–9.
- 37Morita A, Kobayashi K, Isomura I et al. Ultraviolet al (340–400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43: 670–4.
- 38von Kobyletzki G, Uhle A, Pieck C et al. Acrosclerosis in patients with systemic sclerosis responds to low-dose UV-A1 phototherapy. Arch Dermatol 2000; 136: 275–6.
- 39Luftl M, Degitz K, Plewig G, Rocken M. Psoralen bath plus UV-A therapy. Possibilities and limitations. Arch Dermatol 1997; 133: 1597–603.
- 40Pavlotsky F, Sakka N, Lozinski A, Barzilai A. Bath psoralen-UVA photochemotherapy for localized scleroderma: experience from a single institute. Photodermatol Photoimmunol Photomed 2013; 29: 247–52.
- 41Kanekura T, Fukumaru S, Matsushita S et al. Successful treatment of scleroderma with PUVA therapy. J Dermatol 1996; 23: 455–9.
- 42Hofer A, Soyer HP. Oral psoralen-UV-A for systemic scleroderma. Arch Dermatol 1999; 135: 603–4.
- 43Papp G, Horvath IF, Barath S et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 2012; 142: 150–9.
- 44Cribier B, Faradji T, Le Coz C et al. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology 1995; 191: 25–31.
- 45Krasagakis K, Dippel E, Ramaker J et al. Management of severe scleroderma with long-term extracorporeal photopheresis. Dermatology 1998; 196: 309–15.
- 46Neustadter JH, Samarin F, Carlson KR, Girardi M. Extracorporeal photochemotherapy for generalized deep morphea. Arch Dermatol 2009; 145: 127–30.
- 47Schlaak M, Friedlein H, Kauer F et al. Successful therapy of a patient with therapy recalcitrant generalized bullous scleroderma by extracorporeal photopheresis and mycophenolate mofetil. J Eur Acad Dermatol Venereol 2008; 22: 631–3.
- 48Pileri A, Raone B, Raboni R et al. Generalized morphea successfully treated with extracorporeal photochemotherapy (ECP). Dermatol Online J 2014; 20: 21258.
